Home » FDA Clears RLF-100 for COVID-19 Trial
FDA Clears RLF-100 for COVID-19 Trial
The FDA has granted Relief Therapeutics and NeuroRx approval for a phase 2/3 trial of inhaled RLF-100 (aviptadil) for the prevention of respiratory failure in patients with moderate to severe COVID-19 infections.
Aviptadil is a synthetic form of a natural peptide that has been shown to block replication of the SARS-CoV-2 coronavirus in human lung cells and immune cells.
The first phase of the trial will enroll patients hospitalized for severe COVID-19 who do not have respiratory failure. If early results are promising, the trial will be expanded to include patients at home with mild and moderate COVID-19.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May